The "Market Analysis of Hemostat Powder Industry in China 2017-2022" report has been added to ResearchAndMarkets.com's offering.

There are over 4 million patients that went through surgeries every year in China.

In China, Medafor America and BioCer Germany have occupied most of the hemostat powder market for years. In the past few years, most of hemostat powder was imported from overseas countries. However, with technical development, some enterprises have been able to manufacture hemostat powder independently instead of importing. The production volume of domestic hemostat powder is increasing more and more year-by-year. In 2016, the market scale of hemostat powder was over RMB600 million.

With the continuous development and breakthrough in technology of third-category hemostat powder used in surgeries, the domestic enterprises have been able to produce enough hemostat powder to meet the clinical needs. The domestic manufacturers of hemostat powder are believed to occupy more and more market shares in China in the future.

In order to achieve more market shares, domestic manufacturers need to apply for related certificates while investing more to production. It is predicted that the production volume of the third-category hemostat powder will stay at a stable increasing trend in the next few years.

Key Topics Covered:

Executive Summary

Methodology

1 Overview of Hemostat Powder Industry in China

2 Industrial Chain of Hemostat Powder Industry in China

3 Key Players of Hemostat Powder Industry in China

4 Prospect of Hemostat Powder Industry in China

5 Conclusion and Recommendations

Companies Mentioned

  • Bard Healthcare Science (Shanghai) Co., Ltd.
  • Excelle Med-supply (shanghai) Co., Ltd.
  • Qingdao Etsong Bioengineering Co., Ltd.
  • Success Pharmaceutical Group Co., Ltd

For more information about this report visit https://www.researchandmarkets.com/research/jjrwxb/china_hemostat?w=4